DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ABITREXATE
All Clinical Trials for Abitrexate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003702 | Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia | Completed | Eastern Cooperative Oncology Group | Phase 3 | 1999-06-01 | Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia. |
| NCT00003702 | Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-06-01 | Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia. |
| NCT00003702 | Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia | Completed | Gynecologic Oncology Group | Phase 3 | 1999-06-01 | Randomized phase III trial to compare the effectiveness of methotrexate with that of dactinomycin in treating patients who have gestational trophoblastic neoplasia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether methotrexate is more effective than dactinomycin in treating patients with gestational trophoblastic neoplasia. |
| NCT00045305 | Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-05-01 | RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Abitrexate
Condition Name
| Condition Name for Abitrexate | |
| Intervention | Trials |
| Untreated Adult Acute Lymphoblastic Leukemia | 10 |
| Untreated Childhood Acute Lymphoblastic Leukemia | 6 |
| Recurrent Adult Acute Myeloid Leukemia | 6 |
| B Acute Lymphoblastic Leukemia | 6 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
Condition MeSH
Clinical Trial Locations for Abitrexate
Trials by Country
Clinical Trial Progress for Abitrexate
Clinical Trial Phase
Clinical Trial Sponsors for Abitrexate
Sponsor Name
